APA

Cameron D., Morden J. P., Canney P., Velikova G., Coleman R., Bartlett J., Agrawal R., Banerji J., Bertelli G., Bloomfield D., Brunt A. M., Earl H., Ellis P., Gaunt C., Gillman A., Hearfield N., Laing R., Murray N., Couper N., Stein R. C., Verrill M., Wardley A., Barrett-Lee P. & Bliss J. M. (20170911). Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. : The Lancet. Oncology.

Chicago

Cameron David, Morden James P, Canney Peter, Velikova Galina, Coleman Robert, Bartlett John, Agrawal Rajiv, Banerji Jane, Bertelli Gianfilippo, Bloomfield David, Brunt A Murray, Earl Helena, Ellis Paul, Gaunt Claire, Gillman Alexa, Hearfield Nicholas, Laing Robert, Murray Nicholas, Couper Niki, Stein Robert C, Verrill Mark, Wardley Andrew, Barrett-Lee Peter and Bliss Judith M. 20170911. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. : The Lancet. Oncology.

Harvard

Cameron D., Morden J. P., Canney P., Velikova G., Coleman R., Bartlett J., Agrawal R., Banerji J., Bertelli G., Bloomfield D., Brunt A. M., Earl H., Ellis P., Gaunt C., Gillman A., Hearfield N., Laing R., Murray N., Couper N., Stein R. C., Verrill M., Wardley A., Barrett-Lee P. and Bliss J. M. (20170911). Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. : The Lancet. Oncology.

MLA

Cameron David, Morden James P, Canney Peter, Velikova Galina, Coleman Robert, Bartlett John, Agrawal Rajiv, Banerji Jane, Bertelli Gianfilippo, Bloomfield David, Brunt A Murray, Earl Helena, Ellis Paul, Gaunt Claire, Gillman Alexa, Hearfield Nicholas, Laing Robert, Murray Nicholas, Couper Niki, Stein Robert C, Verrill Mark, Wardley Andrew, Barrett-Lee Peter and Bliss Judith M. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. : The Lancet. Oncology. 20170911.